216 related articles for article (PubMed ID: 38140692)
1. Metformin and Hepatocellular Carcinoma Risk Reduction in Diabetic Patients with Chronic Hepatitis C: Fact or Fiction?
Sacco M; Ribaldone DG; Saracco GM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140692
[TBL] [Abstract][Full Text] [Related]
2. Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Tsai PC; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Yeh ML; Huang CF; Hsieh MH; Huang JF; Dai CY; Chung WL; Chen CY; Yu ML;
J Hepatol; 2023 Feb; 78(2):281-292. PubMed ID: 36208843
[TBL] [Abstract][Full Text] [Related]
3. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
4. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
5. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
6. Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.
Tsai PC; Huang CF; Yeh ML; Hsieh MH; Kuo HT; Hung CH; Tseng KC; Lai HC; Peng CY; Wang JH; Chen JJ; Lee PL; Chien RN; Yang CC; Lo GH; Kao JH; Liu CJ; Liu CH; Yan SL; Lin CY; Su WW; Chu CH; Chen CJ; Tung SY; Tai CM; Lin CW; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Chen CY; Huang JF; Dai CY; Wan-Long WL; Bair MJ; Yu ML;
Clin Mol Hepatol; 2024 Apr; ():. PubMed ID: 38637957
[TBL] [Abstract][Full Text] [Related]
7. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
[TBL] [Abstract][Full Text] [Related]
8. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression.
Shen YC; Hsu C; Cheng CC; Hu FC; Cheng AL
Oncology; 2012; 82(5):275-89. PubMed ID: 22555181
[TBL] [Abstract][Full Text] [Related]
9. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.
Kim GA; Han S; Kim HD; An J; Lim YS
J Viral Hepat; 2017 Nov; 24(11):990-997. PubMed ID: 28499070
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients.
Ma L; Liu J; Wang W; Yang F; Li P; Cai S; Zhou X; Chen X; Zhuang X; Zhang H; Cao G
Future Oncol; 2020 Apr; 16(11):675-686. PubMed ID: 32223423
[No Abstract] [Full Text] [Related]
11. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
You MW; Kim KW; Shim JJ; Pyo J
J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
[TBL] [Abstract][Full Text] [Related]
12. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
13. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy.
Huang CF; Yeh ML; Huang CY; Tsai PC; Ko YM; Chen KY; Lin ZY; Chen SC; Dai CY; Chuang WL; Huang JF; Yu ML
Medicine (Baltimore); 2016 Jul; 95(27):e4157. PubMed ID: 27399135
[TBL] [Abstract][Full Text] [Related]
15. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
Nagata H; Nakagawa M; Asahina Y; Sato A; Asano Y; Tsunoda T; Miyoshi M; Kaneko S; Otani S; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Azuma S; Kakinuma S; Nouchi T; Sakai H; Tomita M; Watanabe M;
J Hepatol; 2017 Nov; 67(5):933-939. PubMed ID: 28627363
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.
Kanwal F; Kramer JR; Asch SM; Cao Y; Li L; El-Serag HB
Hepatology; 2020 Jan; 71(1):44-55. PubMed ID: 31222774
[TBL] [Abstract][Full Text] [Related]
17. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents.
Ciancio A; Ribaldone DG; Dotta A; Giordanino C; Sacco M; Fagoonee S; Pellicano R; Saracco GM
Liver Int; 2021 Feb; 41(2):276-287. PubMed ID: 32998174
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis.
Galati G; Muley M; Viganò M; Iavarone M; Vitale A; Dell'Unto C; Lai Q; Cabibbo G; Sacco R; Villa E; Trevisani F
Expert Opin Drug Saf; 2019 Jul; 18(7):603-610. PubMed ID: 31067134
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
